Goldman Sachs Group Inc. Reiterates 126.00 Price Target for Bayer AG
The firm currently has a "buy" rating on the stock. Several other equities research analysts have also recently weighed in on BAYN.
from Biotech News
The firm currently has a "buy" rating on the stock. Several other equities research analysts have also recently weighed in on BAYN.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments